




PrecisionBiotics™

Science in
every strain

Clinical evidence summary

Gastrointestinal health

Bifidobacterium longum 35624™

Contents

The gut microbiome – a target in the management of irritable bowel syndrome (IBS)	3
Introducing <i>Bifidobacterium longum</i> 35624™* and its mechanism of action	4
Guidelines and expert opinion on <i>B. longum</i> 35624™	5
Clinical evidence for <i>B. longum</i> 35624™ in IBS	6
Summary	14
References	15

* In the following text, *Bifidobacterium longum* 35624™ will be referred to as *B. longum* 35624™

Science in every strain

At PrecisionBiotics, we believe that gastrointestinal health is the cornerstone of whole body health, and we are dedicated to unlocking its potential through targeted, evidence-based science. For the past 25 years, we have been at the forefront of microbiome research, isolating, testing and cultivating unique strains with the potential to deliver important health benefits. Each strain in our formulations is backed by extensive data from clinical trials, and real-world observational studies to lend further weight to the evidence behind our products.

The gut microbiome – a target in the management of IBS

The importance of the gut microbiome in human health and disease is well established and our knowledge of its complex composition and potential is growing. The gut microbiome influences human physiology, immune function, metabolism and nutrition. Emerging evidence identifies alterations in the gut microbiota as a core pathogenic mechanism in Disorders of Gut-Brain axis (DGBIs), alongside established mechanisms including gastrointestinal motility, visceral hypersensitivity, CNS processing, and immune activation.¹

The gut microbiome in health

The gut microbiome plays a key role in the regulation of many functions in the body, including:³

- Maintenance of normal gut physiology and health
- Protection against pathogens
- Support of the immune system, digestion, metabolism, insulin sensitivity and secretion
- Modulation of gut-brain communication

The gut microbiome in illness

An imbalanced gut microbiome has been shown to upregulate inflammatory cytokine release in the gut (see page 4, Figure 1a.) and is associated with a number of conditions, including IBS:^{1,2,4}

Randomised, placebo-controlled trials have demonstrated that targeting the gut microbiota, for example by supplementation with certain probiotic strains, can alleviate symptoms of IBS.¹

Strategies for helping manage symptoms of IBS: diet and probiotics

- **Dietary modification can play an important role in IBS management and may influence the composition and function of the gut microbiome. Rome V highlights the importance of diet and the gut microenvironment as key contributors to disorders of DGBIs, including IBS.^{1,5}**
 - In some cases, a low FODMAP (fermentable oligo-, di-, mono-saccharides and polyols) diet or an elimination diet may be advised, but only under the care of a specialist dietitian⁶
- Supplementation of the gut microbiome with specific probiotics has been shown to have a number of strain-specific health benefits.⁷

There is increasing interest in the evidence for probiotics in the management of IBS¹⁻³

Introducing *B. longum* 35624™ – a probiotic strain discovered and researched by PrecisionBiotics

B. longum 35624™ is part of the genus of bacteria called *Bifidobacterium*. Bifidobacteria are among the first types of bacteria to colonise the gut after birth. They are considered to be well adapted to the human gastrointestinal (GI) tract.⁸


Mechanism of action

B. longum 35624™ has a surface covering called exopolysaccharide (EPS), which has a unique structure.^{9,10}

- EPS is important for the viability of *B. longum* 35624™ in the gut^{11,12}
- EPS is also responsible for some of the anti-inflammatory effects of *B. longum* 35624™^{9,10}

Animal models and human clinical trials provide evidence for the immunoregulatory mechanisms of *B. longum* 35624™.^{13,14} Some bacteria have proinflammatory effects, but *B. longum* 35624™ has been shown to engage with dendritic cells, resulting in an anti-inflammatory pathway, as illustrated in Figures 1a and 1b.¹²⁻¹⁴ The introduction of *B. longum* 35624™ into an imbalanced gut microbiome leads to:¹²⁻¹⁴

1. Downregulation of proinflammatory cytokines (e.g. IL-12 and TNF- α)
2. Upregulation of anti-inflammatory cytokines (e.g. IL-10, TGF- β)
3. Activation of regulatory T-cells



B. longum 35624™ has been shown to reduce inflammation, and can help manage IBS symptoms, including abdominal pain, bloating, bowel straining and gas^{2,3,15-18}

Guidelines and expert opinion on *B. longum* 35624™

Globally recognised to help manage IBS symptoms

International clinical guidelines have recognised the potential of specific probiotic strains, including *B. longum* 35624™, in the management of IBS symptoms.¹⁹

The 2024 World Gastroenterology Organisation (WGO) guidelines on probiotics and prebiotics have stated that *B. longum* 35624™ is effective in managing IBS.¹⁹ The WGO also stressed the importance of evidence from human studies when recommending any probiotic in clinical practice.¹⁹

The 2018 European Society for Primary Care Gastroenterology (ESPCG) consensus outlined that *B. longum* 35624™ helps to:²⁰

- Relieve overall symptom burden in some patients with IBS (Evidence grade: High; Agreement: 100%)
- Relieve overall symptom burden in some patients with diarrhoea-predominant IBS (IBS-D) (Evidence grade: Low; Agreement: 100%)
- Reduce abdominal pain in some patients with IBS (Evidence grade: High; Agreement: 100%)
- Reduce bloating/distension in some patients with IBS (Evidence grade: Moderate; Agreement: 75%)
- Improve frequency and/or consistency of bowel movements in some IBS patients (Evidence grade: Moderate; Agreement: 100%)

High evidence:

Probiotics with supportive evidence for benefit should be tried.

Moderate evidence:

Probiotics with supportive evidence for benefit could be tried.

Clinical evidence for *B. longum* 35624™ in helping manage IBS symptoms

Backed by decades of clinical research: With more than 20 scientific publications on gastrointestinal health and 15 on IBS specifically (see table below), including double-blind, placebo-controlled randomised trials, there is a wealth of clinical evidence demonstrating the efficacy of *B. longum* 35624™ in helping to manage IBS symptoms.^{15-18,21-29}

Reference	
O'Mahony <i>et al.</i> 2005 ¹⁵	Double blind, placebo-controlled RCT* - 1 x 10 ¹⁰ CFU/day, 8 weeks, Ireland - 77 adults, IBS (Rome II), all sub-types
Whorwell <i>et al.</i> 2006 ¹⁶	Double blind, placebo-controlled RCT* - 1 x 10 ⁹ CFU/day, 4 weeks, UK - 362 adults, IBS (Rome II), all sub-types
Charbonneau <i>et al.</i> 2013 ²¹	Double blind, placebo-controlled RCT* - 1 x 10 ¹⁰ CFU/day, 12 weeks - 159 adults, IBS
Ünsal <i>et al.</i> 2024 ²²	RCT* - 1 x 10 ⁹ CFU/day, 8 weeks, Turkey - 60 adults, IBS
Emmanuel <i>et al.</i> 2019 ²³	Real-world, open-label study** - 1 x 10 ¹⁰ CFU/day, 8 weeks, France - 43 adults, IBS-D (Rome IV), failed to respond to low-FODMAP diet
Arriaza Peso <i>et al.</i> 2022 ²⁴	Real-world, prospective open-label observational study** - 1 x 10 ⁹ CFU/day, 90 days, Spain - 110 adults, IBS (Rome IV), all sub-types
Sabaté and Iglicki 2022 ¹⁷	Real-world, prospective open-label observational study** - 1 x 10 ⁹ CFU/day, 30 days, France - 233 adults, IBS (Rome IV), all sub-types
Skrypnik <i>et al.</i> 2022 ²⁵	Real-world, prospective open-label study** - 1 x 10 ¹⁰ CFU/day, 8 weeks, Ukraine - 1,260 adults, IBS
Lenoir <i>et al.</i> 2023 ¹⁸	Real-world, open-label, observational study** - 1 x 10 ⁹ CFU/day, 8 weeks, Germany - 37 adults, IBS (Rome IV), all sub-types
Kinnear <i>et al.</i> 2023 ²⁶	Real-world, retrospective online survey** - 1 x 10 ⁹ CFU/day, 3 months, UK - 34 HCPs, 34 adults, IBS
Sorensen K, <i>et al.</i> 2024 ²⁷	Real-world, open-label study** - 1 x 10 ⁹ CFU/day, 12 weeks, China - 305 adults, IBS
Cruchet Muñoz <i>et al.</i> 2024 ²⁸	Paediatric, open-label observational study** - 1 x 10 ⁹ CFU/day, 12 weeks, Chile - 64 children and adolescents (8-18y), IBS (Rome IV)
Sorensen K, <i>et al.</i> 2025 ²⁹	Real-world, open-label study** - 1 x 10 ⁸ CFU/day, 8 weeks, UK - 220 children, IBS

The safety of *B. longum* 35624™ is well documented in human clinical studies, including post-marketing surveillance.³⁰⁻³²

Reported significant improvements in outcomes						
Overall IBS symptom severity	Abdominal pain	Abdominal distension	Bowel movement	Passage of gas	Quality of life	Additional outcomes
✓	✓		✓			Improvement in inflammatory biomarkers (IL10:IL12 ratio)
✓	✓	✓	✓	✓		
						Modification of microbiome colonisation
						Decreased plasma zonulin levels (marker for intestinal integrity)
✓	✓		✓			Improvement in anxiety and depression scores
✓	✓	✓	✓			
✓	✓	✓	✓		✓	
✓	✓		✓		✓	
✓	✓	✓	✓	✓		
✓	✓	✓	✓		✓	
✓	✓	✓	✓		✓	
✓	✓	✓	✓		✓	
✓	✓		✓		✓	

CFU, colony forming unit; FODMAP, fermentable oligo-, di-, mono-saccharides and polyols; HCP, healthcare professional; IBS, irritable bowel syndrome; IBS-D, diarrhoea-predominant IBS; RCT, randomised controlled trial.

* Comparison vs. placebo. ** Comparison vs. baseline.

p≤0.05

p<0.001

B. longum 35624™ can alleviate overall IBS symptoms and help manage every cardinal symptom¹⁵

Study aim:

To compare the IBS symptom response and cytokine ratios of probiotic preparations containing either *B. longum* 35624™ or another strain.

Study method:

- Randomised, double-blind, placebo-controlled study of 77 IBS patients.
- Participants were randomised to receive either *B. longum* 35624™ at 1 x 10¹⁰ (ten billion) colony forming units (CFU), *Lactobacillus salivarius* UCC4331, or a placebo, each daily for 8 weeks, followed by a 4-week washout period.
- The cardinal symptoms of IBS (abdominal pain or discomfort, bloating or distention, and bowel movement difficulty) were recorded daily and assessed each week, and assessment of quality of life and stool microbiology were performed at baseline and at the end of the intervention phase.

Results:

IBS symptoms significantly improved vs. placebo

- Both composite and individual scores for abdominal pain/discomfort, bloating/distention and bowel movement difficulty were significantly ($p < 0.05$) lower vs. placebo for those randomised to receive *B. longum* 35624™ strain for 7 out of 8 weeks of the supplementation period. This was not observed in those who received *L. salivarius* UCC4331 (Table 1).

Effect sustained for a further two weeks

- During the post-supplementation follow-up washout period, those taking *B. longum* 35624™ continued to report symptom improvement for a further 2 weeks, unlike those who received *L. salivarius* UCC4331 (Table 1).

Table 1. Improvements in composite and individual symptom scores for *B. longum* 35624™ and *L. salivarius* UCC4331 vs. placebo


	Supplementation period (weeks)								Follow-up (weeks) No probiotic supplement			
	1	2	3	4	5	6	7	8	9	10	11	12
<i>B. longum</i> 35624™	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗	✗
<i>L. salivarius</i> UCC4331	✗	✓	✗	✗	✗	✗	✗	✗	✗	✗	✗	✗

Adapted from O'Mahony et al. 2005¹⁵

Production of proinflammatory cytokines was normalised

At baseline, individuals with IBS had a significantly lower IL-10:IL-12 ratio vs. healthy volunteers, indicating a proinflammatory state. After taking *B. longum* 35624™, *in vitro* analysis showed the cytokine ratio in the group with IBS was normalised and became comparable with healthy volunteers (Figure 2). This was not observed in those who received *L. salivarius* UCC4331 or placebo.

Figure 2. Comparison of IL-10:IL-12 ratio pre- and post-intervention period



Adapted from O'Mahony et al. 2005¹⁵

Conclusions:

B. longum 35624™ was shown to alleviate overall IBS symptoms and help manage every individual cardinal symptom: abdominal pain/discomfort, bloating/distention, and bowel movement difficulty.

As well as symptomatic improvement in IBS, *B. longum* 35624™ achieved normalisation of the IL-10:IL-12 cytokine ratio, indicating an immunoregulatory response.

These positive outcomes were not observed with the other probiotic strain, highlighting the strain-specific effects of *B. longum* 35624™.

***B. longum* 35624™ was effective in reducing symptoms of IBS within 4 weeks¹⁶**

Study aim:

In a primary care setting, to evaluate the efficacy of different levels of *B. longum* 35624™ in managing IBS symptoms in adult female subjects.

Study method:


- Double-blind, placebo-controlled, multi-centre (20 centres) study of 362 IBS patients.
- Following a 2 week baseline assessment, participants were randomised to receive either placebo or *B. longum* 35624™ at 1×10^6 , 1×10^8 or 1×10^{10} colony forming units (CFU) daily for 4 weeks.
- IBS symptoms were monitored daily and scored on a 6-point Likert scale with primary outcome being abdominal pain or discomfort.
- Other outcome measures included composite IBS symptom score, subjects' global assessment of IBS symptom relief, and quality of life scores.

Results:

IBS symptoms significantly improved vs. placebo

After 4 weeks of supplementation with *B. longum* 35624™ at 1×10^8 CFU per day, significant reduction from baseline was observed vs. placebo for the primary outcome of abdominal pain (-0.89 vs -0.58; $p=0.023$). Additionally, bloating/distension, sense of incomplete evacuation, passage of gas, straining, and bowel habit satisfaction were all significantly improved vs. placebo (Figure 3).

Figure 3. Changes in IBS symptom scores from baseline after 4 weeks of daily supplementation




Adapted from Whorwell et al. 2006¹⁶

†Likert scale used for this outcome was different:
0 = very satisfied and 5 = very dissatisfied

Participants reported significant improvements in IBS symptoms

After 4 weeks of supplementation with *B. longum* 35624™ at 1×10^8 CFU, 62% of participants reported an improvement in their IBS symptoms, compared with 42% in the placebo group ($p < 0.02$) (Figure 4).

Figure 4. Global assessment of IBS symptoms after 4 weeks of daily supplementation with *B. longum* 35624™ or placebo



Adapted from Whorwell et al. 2006¹⁶

Conclusions:

B. longum 35624™ (1×10^8 CFU daily) was shown to be well tolerated and effective in managing the symptoms of IBS within 4 weeks across all subjects, irrespective of bowel habit subtype.

***B. longum* 35624™ was associated with clinically significant reduction in IBS symptom severity after 30-day supplementation¹⁷**

Study aim:

To assess the effect of *B. longum* 35624™ on IBS severity and quality of life in a real-life setting in France.

Study method:


- Prospective, open-label, multi-centre, observational study of 233 subjects with IBS symptoms, according to Rome IV criteria.
- Participants received 1 capsule of *B. longum* 35624™ at 1×10^9 CFU daily for 30 days.

Results:

Improvements in IBS symptoms

- After a 30-day supplementation period with *B. longum* 35624™, significant decrease from baseline in IBS severity was observed (mean $\pm$ SD IBS symptom severity score (IBS-SSS) scores: 208 ± 104 vs. 303 ± 81 , $p < 0.001$), representing a 31% reduction from baseline in mean IBS-SSS score (Figure 5).

Figure 5. Mean IBS-SSS score before and after 30-day supplementation period



Adapted from Sabaté and Iglicki 2022¹⁷

IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; IBS-M, mixed IBS; IBS-U, unidentified subtype IBS.

- After 30 days, significant ($p < 0.001$) reductions vs. baseline were also seen for a range of individual outcomes:
 - ✓ Severity of abdominal pain
 - ✓ Presence and severity of abdominal distension
 - ✓ Bowel habit dissatisfaction
 - ✓ Interference with everyday life
 - ✓ Quality of life (IBS-QoL)

Conclusions:

In adults with IBS defined according to Rome IV criteria, 30-day supplementation with *B. longum* 35624™ was associated with clinically significant reduction in IBS symptoms across all levels of symptom severity vs. baseline in a real-world setting.

***B. longum* 35624™ is associated with significant and meaningful reductions in symptom severity across all IBS subtypes¹⁸**

Study aim:

To assess the effectiveness, safety and tolerability of *B. longum* 35624™ in adults with IBS in Germany in a real-life setting.

Study method:


- Prospective, open-label, multi-centre, observational study of 37 adults diagnosed with IBS according to Rome IV criteria.
- Participants received 1 capsule of *B. longum* 35624™ at 1×10^9 CFU daily for 8 weeks.

Results

Significant IBS symptom improvement

- Significant decrease in IBS severity was observed vs. baseline (mean total IBS symptom score (TISS) scores: 6.97 vs. 12.3, $p < 0.0001$; mean $\pm$ SD IBS-SSS scores: 154 ± 110 vs. 236 ± 102 , $p < 0.001$, Figure 6).

Figure 6. Mean IBS-SSS score before and after an 8-week supplementation period¹⁸



Adapted from Lenoir et al. 2023¹⁸

- *B. longum* 35624™ was associated with significant improvements from baseline in bloating, passage of gas, diarrhoea ($p < 0.0001$ for all), and abdominal pain ($p < 0.001$).

Positive results for quality of life and tolerability

- Quality of life was also improved after 8 weeks vs. baseline ($p < 0.0032$), and over 60% of patients reported they felt adequate relief.
- No serious adverse events were reported and tolerability was rated “very good” or “good” by 89% of participants.

Conclusions:

In adults with IBS, 8-week supplementation with *B. longum* 35624™ in a real-world setting was associated with significant and clinically meaningful reductions in symptom severity vs. baseline across all IBS subtypes.

Summary

A targeted approach that's globally recognised to help manage IBS symptoms

- Clinical guidelines highlight the potential strain-specific benefit of *B. longum* 35624™ for managing the symptoms of IBS.^{19,20}
- Animal models and human clinical trials support the anti-inflammatory and immunoregulatory mechanisms of action of *B. longum* 35624™.¹²⁻¹⁴

Backed by decades of clinical research with more than 25 publications on gastrointestinal health:^{15-18,21-29}


- Randomised controlled trials provide robust evidence that *B. longum* 35624™ significantly helps manage IBS symptoms vs. placebo in:^{15,16,21,22}
 - ✓ Symptom scores for all IBS symptoms
 - ✓ Abdominal pain/discomfort
 - ✓ Bloating/distension
 - ✓ Bowel habit satisfaction
 - ✓ Inflammatory biomarkers
- Real-world, prospective observational cohort studies provide real-world evidence that taking *B. longum* 35624™ delivers significant improvements from baseline in:^{17,18,21-29}
 - ✓ Overall IBS symptom severity scores
 - ✓ Abdominal pain, abdominal distension, bowel habit satisfaction and interference with everyday life
 - ✓ Quality of life and overall wellbeing
- The safety of *B. longum* 35624™ is well documented in human clinical studies, including post-marketing surveillance.^{15-18, 24, 26, 30-31}
- *B. longum* 35624™ has been carefully selected for its safety and efficacy by PrecisionBiotics.

Abbreviations:

B, *Bifidobacterium*; CFU, colony forming unit; EPS, exopolysaccharide; ESPCG, European Society for Primary Care Gastroenterology; FGID, functional gastrointestinal disorder; FODMAP, fermentable oligo-, di-, mono-saccharides and polyols; GI, gastrointestinal; HCP, healthcare professional; IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; IBS-M, mixed IBS; IBS-U, unidentified subtype IBS; IBS-SSS, IBS severity scoring system; IL, interleukin; QoL, quality of life; RCT, randomised controlled trial; SD, standard deviation; TGF, transforming growth factor; TISS, total IBS symptom score system; TNF, tumour necrosis factor; WGO, World Gastroenterology Organisation.

References:

1. Drossman DA, Chang L, Tack J, et al. Disorders of Gut–Brain Interaction and the Rome V Process. *Gastroenterology*. 2026;170(6):1083-109.
2. De Palma G, et al. The microbiota-gut-brain axis in functional gastrointestinal disorders. *Gut Microbes*. 2014;5(3):419-429.
3. Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. *Antonie Van Leeuwenhoek*. 2020;113(12):2019-2040.
4. Schirmer M, et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. *Cell*. 2016;167(4):1125-1136.
5. Leeming ER, et al. Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. *Nutrients*. 2019;11(12).
6. Hill P, et al. Controversies and Recent Developments of the Low-FODMAP Diet. *Gastroenterol Hepatol (N.Y)*. 2017;13(1):36-45.
7. Hill C, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Rev Gastroenterol Hepatol*. 2014;11(8):506-514.
8. O'Callaghan A and van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. *Front Microbiol*. 2016;7:925-925.
9. Schiavi E, et al. The Surface-Associated Exopolysaccharide of *Bifidobacterium longum* 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local T_H17 Responses. *Appl Environ Microbiol*. 2016; 82(24):7185-7196.
10. Altman F, et al. Genome Analysis and Characterisation of the Exopolysaccharide Produced by *Bifidobacterium longum* subsp. *longum* 35624[™]. *PLOS ONE* 2016; 11(9):e0162983.
11. Hidalgo-Cantabrana C, et al. Genomic Overview and Biological Functions of Exopolysaccharide Biosynthesis in *Bifidobacterium* spp. *Applied Environmental Microbiol*. 2014;80(1):9-18.
12. Yan S, et al. Production of exopolysaccharide by *Bifidobacterium longum* isolated from elderly and infant feces and analysis of priming glycosyltransferase genes. *RSC Adv*. 2017;7:31736-31744.
13. Giron F and Quigley EMM. Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. *J Neurogastroenterol Motil*. 2018;24:355-366.
14. Konieczna P, et al. Immunomodulation by *Bifidobacterium infantis* 35624 in the Murine Lamina Propria Requires Retinoic Acid-Dependent and Independent Mechanisms. *PLOS ONE*. 2013;8(5):e62617.
15. O'Mahony L, et al. *Lactobacillus* and *Bifidobacterium* in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles. *Gastroenterol*. 2005;128(3):541-551.
16. Whorwell PJ, et al. Efficacy of an Encapsulated Probiotic *Bifidobacterium infantis* 35624 in Women with Irritable Bowel Syndrome. *Am J Gastroenterol*. 2006;101(7):1581-1590.
17. Sabaté JM, Iglicki F. Effect of *Bifidobacterium longum* 35624 on disease severity and quality of life in patients with irritable bowel syndrome. *World J Gastroenterol*. 2022;28(7):732-744.
18. Lenoir M, et al. An 8 Week Course of *Bifidobacterium longum* 35624[®] Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. *Probiotics Antimicrob Proteins*. 2023;17(1):315-327.
19. Guarner F, et al. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics. *J Clin Gastroenterol*. 2024;58:533-553.
20. Hungin APS, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. *Aliment Pharmacol Ther*. 2018;47:1054-1070.
21. Charbonneau D, et al. Fecal excretion of *Bifidobacterium infantis* 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. *Gut Microbes*. 2013;4(3):201-1.
22. Ünsal NE, et al. Effects of fiber or probiotic yogurt supplementation on intestinal barrier integrity in constipation-predominant irritable bowel syndrome. *Gulhane Med J*. 2024;66(4):176-184.
23. Emmanuel A, et al. The Mexican Association of Gastroenterology National Gastro Week. Mexico 2019.
24. Arriaza Peso E, et al. Efficacy of *Bifidobacterium longum* subsp. *longum* 35624[®] treatment in the symptomatic improvement of irritable bowel syndrome. El Médico, Sanidad y Ediciones, S.L 2022.
25. Skrypnik I, et al. Influence of *Bifidobacterium infantis* 35624 on the clinical course of irritable bowel syndrome depending on the phenotype: results of a local non-interventional prospective epidemiological study IBS-Control. *Modern Gastroenterol*. 2022; <http://dx.doi.org/10.30978/MG-2020-4-13>.
26. Kinnear F, et al. Real world experiences of *Bifidobacterium longum* 35624[®] as part of the long-term management of irritable bowel syndrome symptoms. *J Neurogastroenterol Motility*. 2023;35:e14655.
27. Sorensen K, et al. A real-world study of the effects of *Bifidobacterium longum* 35624[™] on irritable bowel syndrome symptoms in a Chinese population. Presented at FNM 2024;ABS0019.
28. Cruchet Muñoz S, et al. Effects of *Bifidobacterium longum* 35624 in Children and Adolescents with Irritable Bowel Syndrome. *Nutrients*. 2024;16(12):1967.
29. Sorensen K, et al. Correlations between gastrointestinal and wellbeing outcomes following 8 weeks of probiotic supplementation with *Bifidobacterium longum* 35624 in children with irritable bowel syndrome. *J Pediatr Gastroenterol Nutr*. 2025;6(S1):S749-S750.
30. Healy S, et al. The *Bifidobacterium longum* 35624 culture transits in high numbers through the human gut. *Gut*. 2017;66:A25.
31. Quigley E, et al. Tolerability and Safety of the Probiotic *Bifidobacterium infantis* 35624: Review of Clinical and Postmarketing Data. *Am J Gastroenterol*. 2010;105(S480-S481).



Join PrecisionBiotics at the forefront of science and innovation

Join our community of healthcare professionals and be the first to receive the latest information about our scientific work and our product range.

Scan the QR code to visit our website



Disclaimer:

This document is intended exclusively for Healthcare Professionals and is not intended to target consumers nor is it intended to be medical advice or to replace professional consultation or clinical guidance. Products shown are not intended to diagnose, treat, cure or prevent any disease. No statements made shall be construed as approved claims, nor have they been evaluated by the U.S. Food and Drug Administration or similar authorities worldwide. While Novonesis Group (which includes Novozymes A/S and its affiliates, incl. PrecisionBiotics) ensures great care is taken to the accuracy, reliability, and verifiability of the information herein, Novonesis extends no warranty and no liability whatsoever (including any damages for lost profits or business interruption) in that regard nor in regard to its non-infringement of third-party rights, merchantability, or fitness for a particular purpose. Recipients of the information are responsible for determining the conditions of safe use of the information provided (including for regulatory and/or marketing purposes) and whether such use complies with applicable laws and regulations. Copyright© Novonesis Group, by ownership or license. All rights reserved.